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Global cerebral ischemia (GCI) results in death of the pyramidal neurons in the CA1 layer of
the hippocampus. In this study we used the four-vessel occlusion (4VO) model of GCI toAvailable online 28 May 2013
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investigate a potential neuroprotective role of bone-marrow mononuclear cells (BMMCs)
transplantation. BMMCs (3 107) were injected through the carotid artery, 1 or 3 days after
ischemia (DAI), and the number of cells undergoing degeneration was investigated in
brains at 7 DAI. A signiﬁcant decrease in the number of dying cells was observed in the
treated group, compared to animals treated with saline. Biodistribution of the injected cells
(1 or 3 DAI) was investigated by 99mTechnetium labeling of the BMMCs and subsequent
image analysis 2 h after transplantation. In addition, the presence of CellTrace™-labeled
BMMCs was investigated in tissue sections of the hippocampal area of these transplanted
animals. BMMCs treatment signiﬁcantly reduced the number of FJ-C positive cells in the
hippocampal CA1 layer at 7 DAI. We also observed a decrease in the number of activated
microglia/macrophage (ED1-positive cells) in the BMMCs-treated group compared with the
untreated group. Our data show that BMMCs are able to modulate the microglial response
and reduce neurodegeneration in the CA1 layer.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. Elsevier B.V.
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In the United States, 300,000–450,000 individuals suffer
cardiac arrest each year (Callans, 2004), the main cause for
global cerebral ischemia. More than half of the patients who
survive have permanent brain impairment of variable grades
(Pusswald et al., 2000). The brain injury caused by transient
global cerebral ischemia is characterized by a delayed selec-
tive death of CA1 pyramidal neurons in the hippocampus
(Kirino, 1982; Pulsinelli and Brierley, 1979). This region is
critically involved in spatial learning and memory, and the
degeneration of pyramidal neurons results in impairment of
these functions (Bendel et al., 2005; Milani et al., 1998).
Pathophysiological mechanisms in cerebral ischemia
include anaerobic glycolysis, membrane depolarization,
glutamate excitotoxicity, ion imbalance, oxidative stress,
activation of proteases, and inﬂammation (Harukuni and
Bhardwaj, 2006; Rodrigo et al., 2005). These events precede
and contribute to the death of hippocampal CA1 neurons,
which can be detected three days after global ischemia (Block,
1999; Kirino, 1982). The inﬂammatory response after global
cerebral ischemia involves, among other features, reactive
microgliosis in and around the damaged area of the brain,
which can be observed from the ﬁrst days after reperfusion
(Sugawara et al., 2002; Yasuda et al., 2011). This process is
characterized by overactivation of the microglia (the resident
innate immune cells in the brain), and plays an important
role in the progression of the ischemic injury through the
release of cytokines and cytotoxic molecules (Block et al., 2007).
Although some studies have shown beneﬁcial effects of
microglial activation (Lalancette-Hebert et al., 2007; Ohtaki
et al., 2008), most reports indicate that modulation of micro-
glial activation reduces the neuronal death induced by
cerebral ischemia (Franco et al., 2012; Hirko et al., 2008;
Kaundal and Sharma, 2011).
Stem cell therapy has been considered a potential ther-
apeutic alternative for various pathologies of the central
nervous system (CNS) (Hess and Borlongan, 2008; Park et al.,
2010). In particular, the transplantation of bone marrow-
derived cells has shown positive results in preclinical models
of CNS lesions (Lee et al., 2010a; Levy et al., 2008; Zaverucha-
do-Valle et al., 2011), including cerebral ischemia (Brenneman
et al., 2010; de Vasconcelos Dos Santos et al., 2010; Giraldi-
Guimaraes et al., 2009; Vasconcelos-dos-Santos et al., 2012).
Although the mechanisms involved are still under discus-
sion, many studies have demonstrated that transplantation
of bone-marrow mononuclear cells (BMMCs) promotes neu-
roprotection and functional recovery of animals subjected to
focal cerebral ischemia (Franco et al., 2012; Giraldi-Guimaraes
et al., 2009; Yang et al., 2011). Our aim was to investigate
whether similar effects could be observed in a model of global
cerebral ischemia. To our knowledge, only a few studies have
investigated the effect of bone-marrow mesenchymal stem
cells in preclinical models of global cerebral ischemia
(Garbayo et al., 2011; Ohtaki et al., 2008; Perasso et al., 2010;
Wang et al., 2008; Zheng et al., 2010) and only one study
showed the biodistribution of BMMCs but did not investigate
the effects of cell transplantation in the neurodegeneration
and reactive microgliosis, as shown in the present paper(Makela et al., 2013). The advantage of BMMCs is that they
are easily obtained and do not need extensive culturing
before use. In addition, they have proved to be safe in
clinical studies of stroke (Battistella et al., 2011; Friedrich
et al., 2012; Rosado-de-Castro et al., 2013a; Rosado-de-Castro
et al., 2013b).2. Results
2.1. Time course of neurodegeneration in the CA1 layer
after 4VO
Different models of global cerebral ischemia can lead to
different temporal patterns of injury in the CA1 layer of the
hippocampus. In our model we investigated the time course
of neuronal degeneration in the pyramidal layer of CA1,
assessing the number of Fluoro-Jade C (FJ-C)-positive cells 3,
7 and 14 DAI after global cerebral ischemia. We observed an
increase in the number of FJ-C-positive cells from 3 to 7 days
after ischemia (from 17.170.89 cells/mm at 3 DAI to
159.1722.8 cells/mm at 7 DAI). This number decreased in
the following week (114.3716.5 cells/mm) (p¼0.0001; Fig. 1).
We also observed the presence of FJ-C positive cells in the
dentate gyrus as well as in other regions of the brain known
to be vulnerable in this model of ischemia, such as the
striatum and cerebral cortex (data not shown).
2.2. Characterization and biodistribution of the
transplanted BMMCs
The cellular fraction obtained from the bone marrow after
separation by density gradient in Histopaque 1083 was
heterogeneous, with different cell populations. Analysis by
ﬂow cytometry showed that approximately 4% of the ana-
lyzed fraction consisted of hematopoietic precursor cells
(CD45+ and CD34+); 8.0370.39% by monocytes (CD45+ and
CD11b/c+); 48.8713.2% by granulocytes (CD45+/Granulocytes)
and 35.973.5% by immature hematopoietic stem cells (CD45+
and CD90 +).
To investigate the biodistribution and homing of the
injected BMMCs, we labeled the cells with 99mTechnetium
(99mTc) and injected these cells 1 or 3 DAI. The animals were
examined by whole-body scintigraphic imaging 2 h after
transplantation. We observed activity in the injection site
(Fig. 2A and B: non-ischemic rats; C and D: ischemic rats
injected 1 DAI; E and F: ischemic rats injected 3 DAI) and in
the liver and spleen (Fig. 2G and H) but no activity was
distinguished in the brain. After imaging, the animals
(injected 3 DAI) were euthanized, and the brains isolated
and analyzed by gamma-well counting. We observed a
difference between non-ischemic and ischemic groups (2.47
1.610−2% ID/g vs. 11.876.510−2% ID/g; p¼0.0159; Fig. 2I),
suggesting that, although in very low quantity, global
ischemic injury led to an increase in the uptake of 99mTc-
BMMCs in the brain region. However, the short half-life of
99mTc did not allow us to follow the cells for more than 24 h
after injection. In order to investigate the fate of the injected
cells for longer periods, BMMCs were labeled with CellTrace™,
transplanted 1 or 3 DAI and the presence of labeled cells in
Fig. 1 – Time-course of neurodegeneration. Presence of FJ-C positive cells (green) in the CA1 pyramidal layer of the
hippocampus, shown in the photomontage (A). In (B), (C) and (D) ﬂuorescence photomicrographs, showing the degenerating
neurons, labeled with FJ-C, taken from representative sections of animals at 3, 7 and 14 DAI (n¼3 in each group), respectively.
The peak of neuronal degeneration was observed at 7 DAI. Statistical analysis revealed signiﬁcant differences among groups
(E). npo0.05, One-way ANOVA followed by Bonferroni post-hoc. In (A): scale bar¼100 μm; in (B), (C) and (D): scale bar¼50 μm.
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injection. A few labeled cells were found in the hippocampus
of the ischemic animals (Fig. 2J—injected 1 DAI and Fig. 2K—
injected 3 DAI).
2.3. BMMC transplantation has a neuroprotective effect
in the CA1 layer
To investigate whether BMMCs transplantation could pro-
mote neuroprotection in the CA1 region of the hippocampus
in our model, we injected BMMC at 1 DAI or 3 DAI and the
animals were allowed to survive up to 7 DAI. In non-ischemic
animals, FJ-C-positive cells are not present (Fig. 3A). In the
ischemic animals, the number of FJ-C-positive cells at 7 DAI
was signiﬁcantly reduced in the treated animals (BMMC 1
DAI: 66.7710.3 cells/mm; BMMC 3 DAI: 78.3716.6 cells/mm)
compared with the untreated animals (177.6769.9 cells/mm)
(Fig. 3B–D). No difference in neurodegeneration was observedbetween animals who received BMMCs at 1 DAI or at 3 DAI
(p¼0.0004; Fig. 3E).
2.4. BMMCs transplantation reduced microglial activation
in the CA1 layer
Since modulation of the neuroinﬂammatory response has
been suggested as a possible mechanism of action of bone
marrow-derived cell therapies, we evaluated in our model the
presence of activated microglia/macrophages, using immu-
nohistochemistry for the CD68 antigen (ED1) in areas of
neurodegeneration at 7 DAI. In ischemic animals we observed
the presence of ED-1-positive cells in the CA1 layer of the
hippocampus (Fig. 4A), as well as in other brain regions
(data not shown). The number of ED-1-positive cells was
assessed and quantiﬁed at 7 DAI in animals injected
with saline (1105772.37 cells/mm2) or BMMCs 1 DAI (692.87
227.1 cells/mm2) or 3 DAI (497.57205.7 cells/mm2) (Fig. 4B–D).
Fig. 2 – Biodistribution and homing of BMMCs. Representative coronal and sagittal SPECT/CT images of a control animal (A, B)
and of ischemic animals injected 1 DAI (C,D) and injected 3 DAI (E, F) indicating uptake of 99mTc-BMMCs in the injection site;
coronal SPECT/CT image demonstrating uptake in the liver of an ischemic animal injected 3 DAI (G); transversal image
showing uptake in the spleen of an ischemic animal injected 3 DAI (H); Graphic of brain distribution of 99mTc-BMMCs 2 h after
intra-arterial injection in non-ischemic (n¼5) and ischemic (n¼4) rats injected 3 DAI by gamma-well counting (I). Tracer
activity is expressed as the percentage of injected dose per gram of organ (%ID/g) npo0.05 Mann–Whitney test; histological
images of BMMCs labeled with CellTrace (red) in the CA1 layer 6d (J) and 4d (K) after intra-arterial injection. Inset (K′) with
confocal orthogonal image showing CellTrace-positive cell (red) around the nuclei (green). Scale bar¼50 lm.
b r a i n r e s e a r c h 1 5 2 2 ( 2 0 1 3 ) 1 – 1 14The number of ED-1-positive cells in the groups treated with
BMMCs was smaller than in the group that received only
saline (p¼0.0058; Fig. 4E).3. Discussion
Cerebral ischemia can be divided as global, focal, and multi-
focal ischemia. Global ischemia occurs when cerebral blood
ﬂow (CBF) is reduced throughout all of the brain, whereas
focal ischemia is represented by a reduction in blood ﬂow to
a very distinct, speciﬁc brain region. In multifocal ischemia,
there is a patchy pattern of reduced CBF (Traystman, 2003).
Most ischemic strokes occur due to the occlusion of a cerebral
artery by a thrombus. The region of the brain supplied by the
affected artery has a central area of infarction called core or
center and an area around the center area called the penum-
bra, the latter being a potential therapeutic target (Green,2003). In this paper, we use the 4VO method, a speciﬁc model
of global cerebral ischemia, which causes selective death of
CA1 pyramidal neurons in layer of the hippocampus
(Pulsinelli and Brierley, 1979).
In our model, we found a peak of neuronal degeneration in
the CA1 hippocampal layer 7 days after global ischemia,
differing from previous reports. Bendel and colleagues, for
example, reported a peak in neurodegeneration at 14 DAI
(Bendel et al., 2005) in a model that differs from ours mainly
in the time of occlusion (11 min of carotid occlusion) and the
use of two vessels with hypotension (two-vessel occlusion).
We suggest that different models of global cerebral ischemia
can lead to different temporal patterns of injury in the CA1
layer of the hippocampus, and this pattern must be investi-
gated in each model.
One of our goals was to investigate whether the BMMCs
injected into the carotid artery were able to reach the affected
region in the hippocampus. In the present study we were able
Fig. 3 – Neuroprotective effect of BMMCs in the CA1 layer. Representative photomicrographs of hippocampal sections from
non-ischemic animals (A), ischemic animals that received saline (B) and treated with BMMCs 1 (C) or 3 (D) d after ischemia
showing the pattern of Fluoro-Jade positive cells (green). The number of FJ-C-positive cells was lower in the groups treated
with BMMCs at both 1 DAI (n¼4) and 3 DAI (n¼5) compared with the saline-treated group (n¼6). No difference was observed
between the groups that received the BMMCs at 1 DAI or at 3 DAI (E). npo0.05 One-way ANOVA followed by Bonferroni
post-hoc. Scale bar¼50 μm.
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CT camera, which allows better tracking of the cells. Never-
theless, homing could not be distinguished in the brain in the
scintigraphies. Therefore, the uptake of 99mTc-BMMCs in the
brains of non-ischemic and ischemic animals (injected 3 DAI)
was analyzed by gamma-well counting and showed very low
activity in the brain. Although homing in the brain was low,there was higher uptake in the brains of ischemic animals
compared with non-ischemic animals, suggesting that
the global cerebral ischemic event generates an environment
that favors homing of transplanted cells to the brain at
least 2 h after injection. Our group recently reported a
signiﬁcant increase in uptake of radioactivity in the ischemic
hemisphere of animals transplanted with 99mTc -BMMCs
Fig. 4 – Reduction of microglia/macrophages activation in CA1. (A) Photomontage illustrating the presence of ED-1 positive
cells (green) in the CA1 pyramidal layer of the hippocampus of an ischemic animal, 7 DAI. (B, C, D) Representative
photomicrographs, showing ED-1 positive cells in the CA1 layer of ischemic animals that received saline (B), treated with
BMMCs 1 DAI (C) or 3 DAI (D). A lower number of ED-1-positive cells were observed in animals treated with BMMCs 1 or 3 DAI
(n¼3 in each group) compared with the saline-treated group (n¼4) after statistical analysis (E). In (B), (C) and (D) nuclei labeled
with Topro (blue). npo0.05 One-way ANOVA followed by Bonferroni post-hoc. In (A) scale bar¼100 μm; (B), (C) and (D) scale
bar¼50 μm.
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plantation, in a focal cerebral ischemia model (Vasconcelos-
dos-Santos et al., 2012). Homing of labeled cells to the
ischemic lesion was also reported in stroke patients
(Barbosa da Fonseca et al., 2009; Barbosa da Fonseca et al.,
2010; Battistella et al., 2011; Rosado-de-Castro et al., 2013b).
Importantly, the same labeling technique was used in thefocal ischemia study and in our model of global ischemia,
but we were able to show a preferential homing to the
ischemic brain as early as 2 h after transplantation, suggest-
ing that different lesions may lead to differences in cell
homing and biodistribution. The animal and clinical ﬁndings
indicate that, although greater relative homing may occur to
ischemic areas, the total uptake is low in comparison to the
b r a i n r e s e a r c h 1 5 2 2 ( 2 0 1 3 ) 1 – 1 1 7whole-body. Furthermore, to conﬁrm the presence of trans-
planted cells in the brain, we carried out CellTrace labeling
and found few CellTrace-positive cells in the CA1 layer of
ischemic animals injected 1 or 3 DAI. These ﬁndings seem to
accord with previous studies that detected the migration of a
small fraction of the transplanted bone-marrow cells to the
brain in models of focal or global cerebral ischemia (Franco
et al., 2012; Makela et al., 2013; Prabhakar et al., 2010;
Vasconcelos-dos-Santos et al., 2012; Zheng et al., 2010).
Several factors are responsible for the attraction of the
transplanted cells into the ischemic brain. Shen and collea-
gues (Shen et al., 2007) showed that after cerebral ischemia
there is increased expression of stromal-cell-derived-factor-1
(SDF-1) in the infarct region and a concomitant increase in
the speciﬁc receptor for this factor, CXCR4 present in bone
marrow-derived cells. Overexpression of this factor was also
observed by Olstorn and colleagues (Olstorn et al., 2011)
strictly in the CA1 layer of the hippocampus of animals
subjected to global cerebral ischemia. This suggests that the
SDF-1 acts to favor the homing of transplanted stem cells in
different ways to the injured brain area.
However, several studies have shown that the presence of
cells in the ischemic brain is not necessary for the beneﬁcial
effects of cell therapy after intravascular transplantation to
be observed in ischemic animals (Borlongan et al., 2004;
Brenneman et al., 2010; Kamiya et al., 2008), and it has been
suggested that BMMCs may have systemic effects related to
the presence of these cells in organs such as the spleen
(Keimpema et al., 2009; Yang et al., 2011).
Analysis of the neurodegeneration in the CA1 layer after
BMMCs transplantation indicated a reduction in the number
of FJ-C-positive neurons in ischemic animals injected at 1 or 3
DAI and euthanized at 7 DAI, showing that the neuroprotec-
tive effect is maintained even when the transplant is
performed in later periods after the ischemic event. Our
data coincide with previous studies which showed that the
intravascular transplantation of BMMCs in models of stroke
reduces neurodegeneration in ischemic animals (Brenneman
et al., 2010; Franco et al., 2012; Giraldi-Guimaraes et al., 2009;
Kamiya et al., 2008; Nakano-Doi et al., 2010).
Few studies have shown the effects of bone marrow-
derived cell therapy in preclinical models of global cerebral
ischemia (Garbayo et al., 2011; Ohtaki et al., 2008; Perasso
et al., 2010; Wang et al., 2008; Zheng et al., 2010), and all these
studies used bone-marrow mesenchymal stem cells (MSCs).
The beneﬁcial effect observed in our study was similar to that
observed in studies using bone-marrow MSCs in this model
(Garbayo et al., 2011; Perasso et al., 2010; Zheng et al., 2010).
In the present study, we used the mononuclear fraction of
bone marrow, since in a clinical setting the use of these cells
has several advantages over MSC therapy. For example,
BMMCs transplantation shortens the interval between the
onset of ischemia and cell transplantation, since MSCs
require approximately 30 days in culture in order to obtain
a sufﬁcient number of cells, as shown in a clinical trial using
autologous transplantation in patients after acute ischemic
stroke (Bang et al., 2005; Lee et al., 2010a; Lee et al., 2010b).
Therefore, cell transplantation could be applied in less time
for patients suffering for conditions that may lead to global
cerebral ischemia such as cardiac arrest. Furthermore, severalstudies have reported that transplanted BMMCs are safe in
stroke patients (Barbosa da Fonseca et al., 2009; Barbosa da
Fonseca et al., 2010; Battistella et al., 2011; Friedrich et al.,
2012; Mendonca et al., 2006; Savitz et al., 2011).
The mechanisms of action that may result in the neuro-
protective effect observed after bone marrow-derived cell
therapy remain incompletely characterized. However, it is
believed that these cells act indirectly, through paracrine
mechanisms. In our study, we investigated a possible immu-
nomodulatory effect of BMMCs transplantation. We showed
that BMMCs transplantation reduced the reactive microglio-
sis observed in the CA1 layer of the hippocampus of ischemic
animals. It has been suggested that the modulation of the
inﬂammatory response caused by global or focal cerebral
ischemia contributes to the neuroprotective effect observed
after cell therapy (Brenneman et al., 2010; Franco et al.,
2012; Hirko et al., 2008). Ohtaki and collaborators (Ohtaki
et al., 2008) reported that the injection of human MSCs
in the hippocampus resulted in down-regulation of 10% of
ischemia-induced genes, most of them involved in inﬂam-
matory and immune responses. Ohtaki and collaborators also
reported that cell therapy was able to reduce neuronal death
in the hippocampus, indicating a possible relationship
between the modulation of the inﬂammatory response
and the neuroprotective effect, as also found in our study.
Similarly, the immunomodulatory effect of BMMCs was
reported by Brenneman et al. (2010) in an animal-stroke
model; they found that intra-arterial injection of BMMCs
reduced the infarct volume and promoted functional recovery
of ischemic animals. Furthermore, BMMCs therapy reduced
the levels of several proinﬂammatory cytokines (IL-1α, IL-1β,
IL-2, IL-6 and TNF-α) while increasing the levels of an anti-
inﬂammatory cytokine (IL-10) (Brenneman et al., 2010).4. Conclusions
Our data suggest that BMMCs reduce activation of microglia/
macrophages, and result in a neuroprotective effect charac-
terized by a reduction of cell death in the CA1 layer of the
hippocampus. These results suggest that the use of BMMCs
may be a possible therapeutic tool to modulate the effects of
inﬂammatory cells, reduce CA1 pyramidal neuronal death,
and consequently decrease the functional deﬁcit resulting
from global cerebral ischemia.5. Experimental procedures
5.1. Animals
Adult male Wistar rats (250–350 g) were maintained in a
temperature- and light-controlled environment. All proce-
dures were carried out in accordance with the National
Institutes of Health Guidelines for the Care and Use of
Laboratory Animals (NIH Publication no. 80-23) and were
approved by the Institutional Committee for the Use of
Experimental Animals (IBCCF 021).
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Global cerebral ischemia was induced using the four-vessel
occlusion method (4VO) (Pulsinelli and Brierley, 1979) with
some modiﬁcations. The rats were anesthetized with iso-
ﬂuorane in oxygen administered by a mask attached to a
vaporizer. Rectal temperature was monitored before, during
and after ischemia, and maintained at 37.071.0 1C using a
heat lamp. Brieﬂy, the day before surgery, an incision was
made behind the occipital bone directly overlying the ﬁrst
two cervical vertebrae. The paraspinal muscles were sepa-
rated from the midline, the right and left alar foramina of the
ﬁrst cervical vertebrae were exposed, and the vertebral
arteries were permanently occluded by electrocauterization.
Twenty-four hours later, the animals were again anesthe-
tized, the common carotid arteries were exposed through a
ventral midline neck incision and occluded for 17 min using
aneurism clips (Fine Science Tools, Inc.). Anesthesia was
discontinued immediately after initiation of the occlusion.
After the procedure, the skin was sutured and the animals
were kept warm under a heat lamp and returned to the
colony room after they recovered from the surgery. Animals
were excluded if they failed to show pupillary dilation and
loss of the righting reﬂex during the cerebral ischemia. They
also were excluded from the study if they failed to recover
(i.e., resume normal grooming) within 30 min or if they
showed behavioral manifestations such as abnormal vocali-
zation when handled, had generalized convulsions, or showed
hypoactivity.
5.3. BMMCs isolation
BMMCs were isolated from the tibias and femurs of normal
syngeneic donor rats. Brieﬂy, bone marrow was aspirated
from the bones and dissociated with serum-free DMEM-F12
(Gibco BRL, Grand Island, NY, USA) and collected in sterile
tubes. Bone-marrow cells were then mechanically disso-
ciated, centrifuged for 5 min (250 g), and resuspended in
4 ml of DMEM-F12. This volume was gently added over 4 ml of
Histopaque 1083 (Sigma-Aldrich, São Paulo, Brazil) and cen-
trifuged for 30 min (400 g). The cells were collected from the
mononuclear cell region and washed with phosphate-
buffered saline (PBS), pH 7.4 in three consecutive centrifuga-
tions at 250 g (5 min). Following a ﬁnal centrifugation,
approximately 3107 BMMCs were suspended in 300 μl of
saline and either injected immediately in the animals sub-
mitted to the histological analysis, or labeled for localization
analysis.
5.4. Analysis of BMMCs using ﬂow cytometry
The BMMC population was characterized by ﬂow cytometry.
Cells were incubated for 20 min with the following antibo-
dies: anti-CD34-phycoerythrin (PE, Santa Cruz Biotechnology);
anti-CD11b/c-FITC (ﬂuorescein isothiocyanate; Caltag Labora-
tories-Invitrogen), anti-CD45-PE-cyanine 5 (PE-CY5), anti-
Gran-1-FITC and anti-CD90-PE (BD Biosciences, San Jose, CA,
USA). Subsequently, we used a lysing solution (BD Lysing
Solution, BD Biosciences) to lyse erythrocytes, and ﬁxed the
cells. Then, the cells were washed in PBS prior to analysis in aﬂow cytometer (BD FACSAria, BD Biosciences). All antibody
dilutions were 1:100 in PBS. Data analyses were performed
using Inﬁnicyt 1.2 software (Cytognos).
5.5. BMMC labeling with 99mTc or cell trace
BMMCs were labeled with 99mTc following protocols described
previously (Carvalho et al., 2008; Quintanilha et al., 2008;
Vasconcelos-dos-Santos et al., 2012). Brieﬂy, 500 μL of
sterile SnCl2 solution was added to the cell suspension in
phosphate-buffered saline (PBS), and the mixture was incu-
bated at room temperature for 10 min. Then, 5 mCi of 99mTc
was added and the incubation continued for another 10 min.
After centrifugation (500 g for 5 min), the supernatant was
removed and the cells were washed three times with PBS.
Viability of the labeled cells was assessed by the trypan blue
exclusion test, and was estimated to be greater than 93% in
all cases. Labeling efﬁciency (%) was calculated by the activity
in the pellet divided by the sum of the radioactivity in the
pellet plus supernatant, and was estimated to be greater than
90% in all cases. Approximately 3107 99mTc-BMMCs were
injected through the left common carotid artery (IA) imme-
diately after labeling in ischemic rats, 1 or 3 DAI, and in non-
ischemic rats. Whole-body scintigraphies were performed in
these animals for qualitative biodistribution in a dedicated
small animal SPECT/CT camera (Triumph, Gamma-medica
ideas, Canada) equipped with a high-resolution collimator
and diagnostic CT. To compare the radioactivity in the brains
of ischemic animals injected 3 DAI (n¼4) and nonischemic
animals (n¼5), after the completion of the images, the
animals were euthanized and their brains removed and
weighed. The total radioactivity injected in each animal and
the remaining radioactivity in each brain was measured in a
gamma counter (Cobra II Auto-Gamma, Packard, USA). The
percentage of the dose per brain [% dose/organ: each organ
counts/total injected activity100] and the injected dose (ID)
per gram of tissue [%ID/g: % dose/brain/mass (g)] were
determined for each sample.
For histological analysis, 3107 BMMCs were incubated
with CellTrace™ Far Red DDAO-SE (Invitrogen) diluted in
DMEM (1:500) for 45 min at 37 1C in a 5% CO2 incubator, and
injected in two ischemic animals 3 DAI.
5.6. Histological and immunohistochemical analysis
To analyze the time course of neurodegeneration in the CA1
layer, the animals were allowed to survive for 3, 7 or 14 days
after global cerebral ischemia (n¼3 in each group). To analyze
the effect of cell therapy in neurodegeneration and reactive
microgliosis, the animals were allowed to survive for 7 days
after global cerebral ischemia. Animals was euthanized and
ﬁxed with 4% paraformaldehyde in 0.1 M phosphate-buffered
saline, and the brains were removed. After cryoprotection,
coronal sections (20 μm thick) were cut beginning 3.6 mm
from the bregma. The sections were then reacted for Fluoro-
Jade C (FJ-C Histo-Chem Inc.) staining, in accordance to
the manufacturer's instructions (Schmued et al., 2005). For
analysis of the microglial activation, the sections were
subjected to blocking with 5% normal goat serum for 30 min.
Afterwards, these sections were incubated with a primary
b r a i n r e s e a r c h 1 5 2 2 ( 2 0 1 3 ) 1 – 1 1 9antibody, CD-68 (ED1; 1:100; Serotec, Dusseldorf, Germany) at
4 1C overnight, followed by secondary antibody, Alexa Fluor
488-conjugated goat anti-mouse (1:200; Invitrogen) for 2 h at
room temperature. For assessment of tissue damage, three
sections containing regions at a distance of 3.6–4.3 mm
bregma were stained with Fluoro-Jade C (saline, n¼6; BMMCs
1 DAI, n¼4; BMMCs 3 DAI, n¼5) or immunostained for ED1
(saline, n¼4; BMMCs 1 DAI, n¼3; BMMCs 3 DAI, n¼3),
as previously described. The stained cells were counted in
the CA1 layer of the hippocampus, under 20 magniﬁcation,
and expressed as cells/mm for Fluoro-Jade and cells/mm2
for ED-1.
Fluorescence was documented using confocal imaging
microscopy (Zeiss LSM 510META; Carl Zeiss, Gottingen,
Germany) or Apotome microscopy (Carl Zeiss).5.7. Statistical analysis
For statistical comparisons among groups we used Student's
t or Mann–Whitney tests. For analyses that contained more
than two variables, we used one-way ANOVA followed by
Bonferroni post-hoc. Po0.05 was considered statistically sig-
niﬁcant. All analyses were performed using GraphPad Prism
version 5 for Windows (GraphPad Software).Acknowledgments
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